[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:systemic-anaplastic-large-cell-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":15,"states":16},"Systemic Anaplastic Large Cell Lymphoma",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06561048","Soquelitinib vs Standard of Care in Participants With Relapsed\u002FRefractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma",[11],"Phase 3","RECRUITING","2026-08-26T02:15:26.669629Z","2026-05-05T02:43:28.359184Z",[],[]]